Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:
NCT01636102
First received: July 5, 2012
Last updated: December 23, 2013
Last verified: December 2013

July 5, 2012
December 23, 2013
July 2012
July 2012   (final data collection date for primary outcome measure)
  • Percentage of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of TIV [ Time Frame: Day 22 ] [ Designated as safety issue: No ]

    Immunogenicity was measured as the percentage of subjects who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay.

    Seroconversion or significant increase in SRH area was defined as the percentage of subjects with a negative prevaccination serum (SRH area ≤4 mm2) to a postvaccination SRH area ≥25 mm2; or a significant increase in antibody titer from a non-negative prevaccination serum, i.e., at least a 50% increase in area. The European (CHMP) criterion is met if percentage of subjects achieving seroconversion or significant increase in SRH area is >40% (≥18 years to ≤60 years) or 30% (≥61 years).

  • Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains After One Vaccination of TIV [ Time Frame: Day 22 ] [ Designated as safety issue: No ]

    Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination SRH geometric mean areas (GMAs), directed against each of three vaccine strains, three weeks after vaccination (day 22).

    The CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is >2.5 (≥18 years to ≤60 years) or >2.0 (≥61 years).

  • Percentage of Subjects Who Achieved SRH Area ≥25 mm2 Against Each of Three Vaccine Strains After One Vaccination of TIV [ Time Frame: Day 1 and 22 ] [ Designated as safety issue: No ]

    Immunogenicity was measured as the percentage of subjects achieving SRH area ≥25 mm2 against each of three vaccine strains at baseline (day 1) and three weeks after TIV vaccination (day 22).

    This criterion was met according to CHMP guideline if percentage of subjects achieving SRH area ≥25 mm2 is >70% (≥18 years to ≤60) or 60% (≥61 years).

  • Local and systemic reactions [ Time Frame: 4 days (day 1 to day 4) ] [ Designated as safety issue: Yes ]
  • All adverse events [ Time Frame: 4 days (day 1 to day 4) ] [ Designated as safety issue: Yes ]
  • Adverse events necessitating a physician's visit or consultation and/or leading to premature study discontinuation and SAEs [ Time Frame: Day 5 to end of study ] [ Designated as safety issue: Yes ]
  • Antibody response to each influenza vaccine antigen, as measured by single radial hemolysis (SRH) in adult and elderly subjects. [ Time Frame: 21 days postvaccination ] [ Designated as safety issue: No ]
    In compliance with the requirements of the current EU recommendations for clinical trials related to yearly licensing of influenza vaccines.
  • Hemagglutination inhibition (HI) [ Time Frame: 21 days postvaccination ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01636102 on ClinicalTrials.gov Archive Site
Numbers of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 - Day 4 Postvaccination) [ Time Frame: From day 1 through day 4 postvaccination ] [ Designated as safety issue: Yes ]
Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 up to and including day 4 after the TIV vaccination.
Not Provided
Not Provided
Not Provided
 
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine (Agrippal®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects

To evaluate the safety of a single intramuscular (IM) injection of trivalent nonadjuvated influenza study vaccine, formulation 2012/2013, in adult and elderly subjects and the antibody response to each influenza vaccine antigen, as measured by single radial hemolysis (SRH) and hemagglutination inhibition (HI) at approximately 21 days postimmunization in adult and elderly subjects in compliance with the requirements of the current EU recommendations for clinical trials related to yearly licensing of influenza vaccines.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Human Influenza
Biological: Trivalent influenza virus vaccine (TIV)
A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
Experimental: Arm 1
Intervention: Biological: Trivalent influenza virus vaccine (TIV)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
126
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male and female volunteers of 18 years of age or older;
  2. Individuals able to comply with all the study requirements;
  3. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator

Exclusion Criteria:

  1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, could have interfered with the subject's ability to participate in the study.
  2. Individuals with any serious chronic or acute disease (in the judgment of the investigator), including but not limited to:

    • Medically significant cancer (except for benign or localized skin cancer, cancer in remission for ≥10 years or localized prostate cancer that has been clinically stable for more than 2 years without treatment);
    • Medically significant advanced congestive heart failure (ie. NYHA class III and IV);
    • Chronic obstructive pulmonary disease (COPD; i.e., GOLD Stage III and IV);
    • Autoimmune disease (including rheumatoid arthritis, except for Hashimoto's thyroiditis that has been clinically stable for ≥5 years);
    • Diabetes mellitus type I;
    • Poorly controlled diabetes mellitus type II;
    • Advanced arteriosclerotic disease;
    • History of underlying medical condition such as major congenital abnormalities requiring surgery, chronic treatment, or associated with developmental delay (e.g., Down's syndrome);
    • Acute or progressive hepatic disease;
    • Acute or progressive renal disease;
    • Severe neurological (es. Guillain-Barré syndrome) or psychiatric disorder;
    • Severe asthma.
  3. Individuals with history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g. to eggs or eggs product as well as ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate).
  4. Individuals with known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:

    • receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;
    • receipt of immunostimulants;
    • receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study;
    • suspected or known HIV infection or HIV-related disease.
  5. Individuals with known or suspected history of drug or alcohol abuse.
  6. Individuals with a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion could have interfered with the safety of the subject.
  7. Individuals who were not able to comprehend and to follow all required study procedures for the whole period of the study.
  8. Individuals with history or any illness that, in the opinion of the investigator, posed additional risk to the subjects due to participation in the study.
  9. Individuals who within the past 6 months have:

    • had any laboratory confirmed seasonal or pandemic influenza disease;
    • received any seasonal or pandemic influenza vaccine.
  10. Individuals who received any other vaccine within 4 weeks prior to enrollment in this study or who were planning to receive any vaccine during the study.
  11. Individuals with any acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
  12. Individuals who experienced fever (i.e., axillary temperature ≥38°C) within the last 3 days of intended study vaccination.
  13. Individuals participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
  14. Individuals who were part of study personnel or close family members conducting this study.
  15. BMI >35 kg/m2.
  16. Females who were pregnant (confirmed by positive urine pregnancy test) or nursing (breastfeeding). Females of childbearing potential who refused to use an acceptable method of birth control for the whole duration of the study.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01636102
V71_32S, 2012-000063-24
No
Novartis ( Novartis Vaccines )
Novartis Vaccines
Not Provided
Study Chair: Novartis Vaccines and Diagnostics Novartis Vaccines
Novartis
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP